share_log

C4 Therapeutics | 10-Q: Q2 2024 Earnings Report

C4 Therapeutics | 10-Q: Q2 2024 Earnings Report

C4 Therapeutics | 10-Q：2024財年二季報
美股sec公告 ·  08/01 07:31
Moomoo AI 已提取核心訊息
C4 Therapeutics, a clinical-stage biopharmaceutical company, has not reported any revenue as of June 30, 2024, with its financial performance primarily driven by collaboration agreements. The company has ongoing agreements with Roche, Biogen, and Calico, focusing on the development of treatments for cancer and neurological conditions. Under the Roche Agreement, C4 Therapeutics received an upfront payment of $40 million and may receive milestone payments up to $273 million, plus royalties on net sales. The company also has a collaboration with Biogen for novel treatments for neurological conditions, with potential milestone payments of up to $35 million per target. The Calico Agreement, which ended in March 2023, could yield up to $132 million in development and commercial milestone payments. Revenue from these collaborations for the first half of 2024 totaled $15.045 million, a significant increase from $6.423 million in the same period of 2023. The company's future plans include advancing clinical trials for its product candidates, such as cemsidomide for multiple myeloma and non-Hodgkin lymphomas, and CFT1946 for BRAF V600X mutant solid tumors.
C4 Therapeutics, a clinical-stage biopharmaceutical company, has not reported any revenue as of June 30, 2024, with its financial performance primarily driven by collaboration agreements. The company has ongoing agreements with Roche, Biogen, and Calico, focusing on the development of treatments for cancer and neurological conditions. Under the Roche Agreement, C4 Therapeutics received an upfront payment of $40 million and may receive milestone payments up to $273 million, plus royalties on net sales. The company also has a collaboration with Biogen for novel treatments for neurological conditions, with potential milestone payments of up to $35 million per target. The Calico Agreement, which ended in March 2023, could yield up to $132 million in development and commercial milestone payments. Revenue from these collaborations for the first half of 2024 totaled $15.045 million, a significant increase from $6.423 million in the same period of 2023. The company's future plans include advancing clinical trials for its product candidates, such as cemsidomide for multiple myeloma and non-Hodgkin lymphomas, and CFT1946 for BRAF V600X mutant solid tumors.
臨床階段生物醫藥公司c4 therapeutics截至2024年6月30日尚未報告營業收入，其業績主要來源於合作協議。該公司與Roche、渤健公司和Calico簽訂了持續的合作協議，專注於癌症和神經系統疾病治療的開發。根據與Roche簽訂的協議，c4 therapeutics獲得了4000萬美元的首付款，並可能獲得高達27300萬美元的階段性付款和淨銷售額的特許權使用費。該公司還與渤健公司合作研發新型神經系統疾病治療，每個目標的潛在階段付款高達3500萬美元。Calico協議於2023年3月結束，開發和商業化階段的里程碑支付最高可達13200萬美元。截至2024年上半年，這些合作協議的收入總計爲1504.5萬美元，大幅增長，高於2023年同期的642.3萬美元。該公司未來計劃包括推進其產品候選的臨床試驗，例如治療多發性骨髓瘤和非何傑金淋巴瘤的Cemsidomide以及用於BRAF V600X突變實體瘤的CFT1946。
臨床階段生物醫藥公司c4 therapeutics截至2024年6月30日尚未報告營業收入，其業績主要來源於合作協議。該公司與Roche、渤健公司和Calico簽訂了持續的合作協議，專注於癌症和神經系統疾病治療的開發。根據與Roche簽訂的協議，c4 therapeutics獲得了4000萬美元的首付款，並可能獲得高達27300萬美元的階段性付款和淨銷售額的特許權使用費。該公司還與渤健公司合作研發新型神經系統疾病治療，每個目標的潛在階段付款高達3500萬美元。Calico協議於2023年3月結束，開發和商業化階段的里程碑支付最高可達13200萬美元。截至2024年上半年，這些合作協議的收入總計爲1504.5萬美元，大幅增長，高於2023年同期的642.3萬美元。該公司未來計劃包括推進其產品候選的臨床試驗，例如治療多發性骨髓瘤和非何傑金淋巴瘤的Cemsidomide以及用於BRAF V600X突變實體瘤的CFT1946。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息